Litigation Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

« Back to Dashboard

OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

Docket		Date Filed	2014-07-25
Court	District Court, D. New Jersey	Date Terminated	2017-09-29
Cause	35:271 Patent Infringement	Assigned To	Jerome B. Simandle
Jury Demand		Referred To	Karen M. Williams
Patents	8,017,615; 8,580,796; 8,642,760; 8,759,350
Link to Docket	External link to docket

Details for OTSUKA PHARMACEUTICAL CO., LTD. v. TORRENT PHARMACEUTICALS LIMITED (D.N.J. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-07-25				External link to document

Otsuka Pharmaceutical v. Torrent Pharmaceuticals: Patent Litigation Summary and Generic Entry Analysis

Last updated: August 2, 2026

Otsuka Pharmaceutical Co., Ltd. sued Torrent Pharmaceuticals Limited in the U.S. District Court for the District of New Jersey after Torrent filed an abbreviated new drug application for generic aripiprazole tablets, the active ingredient in Abilify. The case, No. 1:14-cv-04671, was a Hatch-Waxman patent dispute centered on U.S. Patent No. 8,017,615. The litigation was resolved by dismissal rather than a reported merits judgment. Public docket materials do not disclose the commercial terms of any settlement or license agreement.

What was Otsuka Pharmaceutical v. Torrent Pharmaceuticals about?

The case concerned Torrent's proposed generic version of Otsuka's Abilify tablets. Abilify contains aripiprazole, an atypical antipsychotic approved for schizophrenia, bipolar disorder, adjunctive treatment of major depressive disorder, and certain pediatric indications.

Otsuka and related entities asserted patent infringement under 35 U.S.C. § 271(e)(2), the statutory mechanism used when a generic applicant files an ANDA with a Paragraph IV certification challenging an Orange Book-listed patent.

Item	Case detail
Court	U.S. District Court for the District of New Jersey
Case number	1:14-cv-04671
Plaintiff	Otsuka Pharmaceutical Co., Ltd., with related Otsuka entities
Defendant	Torrent Pharmaceuticals Limited
Branded product	Abilify
Active ingredient	Aripiprazole
Dosage form	Oral tablets
Regulatory pathway	ANDA
ANDA identified in public case materials	ANDA No. 205874
Principal asserted patent	U.S. Patent No. 8,017,615
Filing period	2014
Resolution	Dismissal; no reported merits decision
Public settlement terms	Not disclosed

The complaint followed Torrent's Paragraph IV certification that the relevant patent was invalid, unenforceable, or would not be infringed by Torrent's proposed product. The filing triggered the 30-month stay under the Hatch-Waxman Act, subject to the statutory and regulatory conditions applicable at the time. (Otsuka Pharmaceutical Co. v. Torrent Pharmaceuticals Ltd., 1:14-cv-04671, D.N.J. 2014; FDA, 2023.)

What patent protected Abilify in the Torrent litigation?

The central patent was U.S. Patent No. 8,017,615, generally associated with aripiprazole and its medicinal use. The patent issued on September 13, 2011, from an application claiming priority to an earlier Otsuka filing. Its listed expiration date was April 20, 2021, before any applicable pediatric-extension adjustment.

The patent was important because the basic compound patent for aripiprazole had a different expiration profile. The earlier aripiprazole patent, U.S. Patent No. 5,006,528, was litigated in earlier Otsuka cases and did not provide the same remaining term in the 2014 Torrent dispute. Otsuka therefore relied on later patent protection to delay generic entry.

Patent profile

Patent	Subject matter	Relevance to Abilify	Approximate expiration
U.S. Patent No. 5,006,528	Aripiprazole and related carbostyril derivatives	Earlier compound protection	Expired before the Torrent case was resolved
U.S. Patent No. 8,017,615	Aripiprazole medicinal-use claims	Principal patent asserted against Torrent	April 20, 2021, subject to any applicable pediatric extension
Other Abilify-related listings	Product, use, or formulation claims depending on dosage form and indication	Potentially relevant to other ANDAs	Varied by patent

The precise scope of the '615 patent depended on the asserted claims and Torrent's proposed labeling. In Hatch-Waxman litigation, the infringement analysis is based on the ANDA, proposed labeling, formulation, manufacturing process, and certification. A generic applicant does not need to copy every aspect of the branded product to create a justiciable infringement dispute.

When did Torrent file its generic aripiprazole application?

Torrent filed ANDA No. 205874 for aripiprazole tablets before the expiration of Otsuka's listed patent. Otsuka filed the New Jersey action in 2014 after receiving Torrent's Paragraph IV notice.

The case chronology was:

Date or period	Event
Before 2014	Otsuka held Orange Book-listed patent protection associated with Abilify
2014	Torrent filed an ANDA and delivered a Paragraph IV certification
July 2014	Otsuka filed the infringement action in the District of New Jersey
2014-2015	The parties litigated the patent dispute and regulatory timing issues
Resolution period	The case was dismissed without a reported trial judgment
2021	The listed term of U.S. Patent No. 8,017,615 reached its scheduled expiration, subject to pediatric-extension treatment

The 2014 filing date placed the dispute within the period when Abilify generated substantial U.S. sales and when generic aripiprazole entry represented a significant commercial threat.

What was the Paragraph IV challenge in the Torrent case?

Torrent's Paragraph IV certification challenged the legal basis for Otsuka's patent exclusivity. A Paragraph IV certification asserts that an Orange Book-listed patent is invalid, unenforceable, or not infringed by the ANDA product.

That certification creates two consequences:

1. It gives the brand company a statutory basis to file an infringement action before commercial launch.
2. It can trigger a 30-month stay of FDA approval, unless the litigation is resolved earlier or the stay is otherwise terminated.

The Paragraph IV challenge did not itself establish that Torrent's product infringed. It created the procedural pathway for Otsuka to seek a judgment before FDA approval and launch.

The public record does not show a reported claim-construction ruling, summary-judgment decision, or trial verdict in the Torrent action. The absence of a merits decision means the docket does not provide a judicial finding that the '615 patent was valid, infringed, or enforceable against Torrent.

What was the litigation status and how was the case resolved?

The case ended by dismissal rather than a published merits opinion. A dismissal generally indicates that the parties reached a resolution, abandoned the dispute, or otherwise agreed that continued litigation was unnecessary. In Hatch-Waxman matters, dismissal commonly follows a confidential settlement that addresses generic launch timing, patent rights, and possible licenses.

The public docket does not disclose:

• Torrent's agreed launch date;
• Whether Torrent received a license;
• Whether the agreement included a royalty;
• Whether the agreement included a no-authorized-generic provision;
• Whether Otsuka granted supply or distribution rights;
• Whether the agreement contained acceleration, forfeiture, or co-promotion provisions.

No public source cited here establishes that Torrent received a license to launch before patent expiration. The dismissal should therefore not be treated as evidence of an agreed early-entry date.

Did Otsuka win the Torrent case?

There was no reported merits victory for Otsuka. The case did not produce a public decision upholding the asserted patent against Torrent, and there was no reported judgment of infringement.

From a business perspective, Otsuka achieved the immediate procedural objective of forcing the Paragraph IV dispute into federal court. The commercial outcome cannot be quantified from the public dismissal alone because the settlement terms were not reported.

Did Torrent invalidate the Abilify patent?

No. Torrent did not obtain a reported judgment invalidating U.S. Patent No. 8,017,615 in this case. A dismissal is not an invalidity ruling.

The later expiration of the patent also did not result from a Torrent judgment. Patent expiry occurred by operation of law at the end of the statutory term, subject to any applicable patent-term adjustment or pediatric extension.

What was the FDA and Orange Book status of Abilify?

Abilify was approved by the FDA as an aripiprazole product. The FDA Orange Book listed patents for Abilify and related products, including the patent at issue in the Torrent case during the relevant period. The Orange Book listing gave Otsuka a basis to receive notice of ANDA certifications and to file a Hatch-Waxman action. (FDA, 2023.)

FDA approval and patent enforceability are separate issues. The FDA evaluates the ANDA for pharmaceutical equivalence, bioequivalence, manufacturing quality, labeling, and safety-related requirements. The federal court determines patent infringement and validity.

A generic aripiprazole applicant could pursue several certification strategies:

• Paragraph I, if no patent information had been submitted;
• Paragraph II, if the listed patent had expired;
• Paragraph III, if the applicant accepted approval effective after patent expiration;
• Paragraph IV, if the applicant challenged validity, enforceability, or infringement;
• A section viii statement, if the applicant carved out a patented indication from its labeling.

The Torrent case arose from the Paragraph IV pathway. The commercial value of that strategy depended on the scope of the proposed label and the remaining patent term.

What generic entry risks existed for Otsuka?

Otsuka faced a material generic-entry risk because aripiprazole was a small-molecule product with a relatively straightforward oral-tablet dosage form. Unlike a biologic, aripiprazole does not face biosimilar interchangeability issues or the manufacturing complexity associated with monoclonal antibodies.

The primary risks were:

Early generic launch

If Torrent prevailed on invalidity or non-infringement, or if the parties agreed to an early launch, generic aripiprazole could enter before the '615 patent expired.

Label-based non-infringement

Torrent could seek to omit patented uses from its labeling. A successful section viii carve-out could reduce Otsuka's ability to block approval based on method-of-use claims.

Multiple generic applicants

The Torrent case was part of a broader generic challenge environment around aripiprazole. Multiple ANDA filers could create price competition soon after the first launch. The first approved generic or first commercial entrant would generally have an advantage in distribution, pharmacy substitution, and contract negotiations.

Revenue erosion

Abilify had been a major product for Otsuka and its commercial partners. Generic entry in a high-volume oral solid market typically produces rapid price erosion, with the degree depending on the number of entrants, payer substitution, authorized-generic strategy, and launch timing.

Public materials associated with this case do not establish the portion of Otsuka's revenue attributable specifically to Torrent's ANDA. A case-level revenue figure should not be inferred from total Abilify sales.

How strong was Otsuka's patent estate against Torrent?

The patent estate was legally meaningful but narrower than a basic compound patent estate.

Strengths

The '615 patent had years of remaining term when Otsuka sued in 2014. That remaining term supported a litigation-based delay strategy and gave Otsuka leverage in settlement negotiations.

The patent was listed in the Orange Book, allowing Otsuka to invoke the Hatch-Waxman litigation framework. The product's commercial importance also increased the value of an enforceable use or formulation patent.

Weaknesses

The underlying aripiprazole molecule was an established pharmaceutical compound by the time of the Torrent case. Later patents generally face greater obviousness and claim-scope challenges than foundational composition-of-matter patents.

The strength of Otsuka's position depended on the actual asserted claims. A method-of-use patent can be vulnerable to a label carve-out, while a formulation patent may not cover a conventional generic tablet using different excipients or manufacturing parameters.

The Torrent docket did not generate a published ruling testing the '615 patent's validity or infringement. Patent strength therefore must be assessed from the patent claims, prosecution history, Orange Book listing, and outcomes in related cases rather than from the Torrent dismissal.

Were there licensing deals or settlement agreements?

The case was dismissed, which is consistent with a settlement or other negotiated resolution. The public record cited here does not disclose the terms.

There is no basis in the public docket to conclude that the agreement included:

• An authorized generic;
• A royalty-bearing license;
• A supply agreement;
• A launch date before April 2021;
• A launch date after pediatric exclusivity;
• A restriction on Torrent's challenge to other Otsuka patents.

Confidential Hatch-Waxman settlements can materially alter the effective exclusivity period. Without the agreement's terms, the case should be classified as legally resolved but commercially opaque.

Did the case involve biosimilar risk?

No. The case involved a conventional generic small-molecule drug, not a biologic and not a biosimilar under the Biologics Price Competition and Innovation Act.

The relevant competitive risks were ANDA approval, Paragraph IV litigation, patent expiry, labeling carve-outs, and generic price competition. Biosimilar interchangeability, reference-product exclusivity under the Public Health Service Act, and biologic manufacturing comparability were not relevant to Torrent's aripiprazole tablets.

What manufacturing and geographic barriers affected the dispute?

Torrent's proposed product was an oral tablet, so the main technical barriers were pharmaceutical equivalence, bioequivalence, formulation reproducibility, content uniformity, dissolution, stability, and current good manufacturing practice compliance.

The patent dispute was U.S.-specific. The District of New Jersey action addressed U.S. patent rights and the FDA ANDA. It did not determine:

• Canadian or European patent rights;
• Indian patent rights;
• Regulatory approval outside the United States;
• Manufacturing rights in other jurisdictions;
• Distribution rights for non-U.S. markets.

Torrent's global manufacturing capacity could affect commercial launch economics, but the U.S. court's jurisdiction was limited to the asserted U.S. patent and the ANDA-related infringement controversy.

How does this case compare with Otsuka's other aripiprazole litigation?

The Torrent action should be distinguished from earlier Otsuka litigation involving U.S. Patent No. 5,006,528. In Otsuka Pharmaceutical Co. v. Sandoz, Inc., the Federal Circuit addressed the validity of aripiprazole-related composition claims and upheld the patent claims at issue under the record presented. That decision did not resolve the Torrent case and should not be treated as a direct judgment on U.S. Patent No. 8,017,615. (Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280, 2012.)

Issue	Otsuka v. Sandoz	Otsuka v. Torrent
Main product	Aripiprazole	Aripiprazole tablets
Principal patent context	Earlier aripiprazole patent	U.S. Patent No. 8,017,615
Litigation posture	Reported appellate merits decision	Dismissed without reported merits decision
Patent validity ruling	Yes, for claims addressed in that case	No reported ruling
Commercial implication	Supports analysis of earlier patent strength	Leaves Torrent's commercial resolution undisclosed

Key Takeaways

• Otsuka sued Torrent in 2014 over an ANDA for generic aripiprazole tablets.
• The case was a Hatch-Waxman Paragraph IV dispute involving U.S. Patent No. 8,017,615.
• The patent was associated with Abilify and had an approximate April 20, 2021 expiration date before any applicable pediatric extension.
• The litigation ended by dismissal, with no reported judgment on validity, infringement, or enforceability.
• Public records do not disclose Torrent's launch date, royalty obligations, license rights, or other settlement terms.
• The case involved a generic small-molecule drug, not a biosimilar.
• The principal commercial risk to Otsuka was early generic entry into a high-volume oral-tablet market.
• Later expiration of the patent was not the result of a Torrent invalidity judgment.
• The case has limited precedential value because it produced no reported merits opinion.

FAQs

What ANDA did Torrent file for generic Abilify?

Torrent's application was identified in public case materials as ANDA No. 205874 for aripiprazole tablets.

Was U.S. Patent No. 8,017,615 invalidated in court?

No reported decision in Otsuka v. Torrent invalidated the patent. The case ended by dismissal.

Did Torrent launch generic aripiprazole before Abilify patent expiry?

The public dismissal materials cited here do not disclose a negotiated launch date or establish an early launch right.

Is Abilify protected by a biologic exclusivity period?

No. Abilify is a small-molecule drug regulated through the NDA and ANDA framework, not the biologic and biosimilar framework.

What is the principal investment implication of the case?

The case shows that Otsuka had enforceable litigation leverage in 2014 but that the public record does not reveal whether the dispute preserved the full remaining patent term or permitted an earlier Torrent launch.

References

Food and Drug Administration. (2023). Approved drug products with therapeutic equivalence evaluations: The Orange Book. U.S. Department of Health and Human Services. https://www.fda.gov/drugs/drug-approvals-and-databases/approved-drug-products-therapeutic-equivalence-evaluations-orange-book

Otsuka Pharmaceutical Co. v. Sandoz, Inc., 678 F.3d 1280 (Fed. Cir. 2012).

Otsuka Pharmaceutical Co., Ltd. v. Torrent Pharmaceuticals Limited, No. 1:14-cv-04671, U.S. District Court for the District of New Jersey (2014).

U.S. Patent No. 8,017,615. (2011). Carbostyril derivative and medicinal use thereof. U.S. Patent and Trademark Office.

U.S. Patent No. 5,006,528. (1991). Carbostyril derivatives. U.S. Patent and Trademark Office.